Date:8/6/2009

- ------ ------ ------ ------ Total costs and expenses 29,484 22,453 55,949 41,192 Operating loss (20,316) (9,608) (38,093) (17,772) Interest income and other, net 162 162 470 542 Loss on marketable securities (38) (240) (38) (1,069) ------- ------ ------- ------- Loss before incomes taxes (20,192) (9,686) (37,661) (18,299) Deferred tax expense (54) (57) (74) (70) --- --- --- --- Net loss $(20,246) $(9,743) $(37,735) $(18,369) ======== ======= ======== ======== Weighted average shares outstanding, basic and diluted 61,138 47,147 61,079 46,239 Net loss per share, basic and diluted: $(0.33) $(0.21) $(0.62) $(0.40) ====== ====== ====== ====== Consolidated Balance Sheet Information June 30, December 31, 2009 2008 -------- ------------ Assets: (unaudited) (audited) Cash, cash equivalents and short-term marketable securities $63,589 $98,329 Restricted cash 1,416 1,371 Accounts receivable, net 7,520 10,642 Inventories, net 10,464 10,631 Othe
'/>"/>

SOURCE SEQUENOM, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related biology technology :

1. SEQUENOM Announces Launch of MassARRAY Compact 96 System
2. SEQUENOM to Hold First Quarter 2009 Financial Results Conference Call on April 30
3. Webcast Alert: Sequenom: Defining the Future of Noninvasive Prenatal Diagnostics
4. Sequenom to Webcast Analyst and Investor Briefing Presentation on June 3
5. Sequenom to Webcast Analyst and Investor Briefing Presentation on September 24
6. OncoGenex Reports Second Quarter 2009 Financial Results
7. Repligen Reports First Quarter Fiscal Year 2010 Financial Results
8. PDI Reports 2009 Second Quarter Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
10. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
11. NxStage Reports Second Quarter 2009 Financial Results